Braidwell LP Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Braidwell LP boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 493,687 shares of the company’s stock after purchasing an additional 126,836 shares during the period. Braidwell LP’s holdings in Dianthus Therapeutics were worth $13,517,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of DNTH. Vanguard Group Inc. boosted its position in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Dianthus Therapeutics in the first quarter worth $11,251,000. Great Point Partners LLC boosted its position in Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $23.83 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $6.58 and a 52-week high of $33.77. The firm has a market cap of $705.37 million, a price-to-earnings ratio of -9.53 and a beta of 1.84. The business’s fifty day moving average is $26.74 and its 200 day moving average is $26.57.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DNTH. Wedbush cut their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Raymond James boosted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.